Involutional Osteoporosis: Sarcopenia, Frailty Syndrome and Falls

Chapter
First Online:

Abstract

Our society is doomed to struggle against pandemic of civilization diseases. One of the most common of them is osteoporosis. There are several reasons for it, one of the most significant of which is lengthening of human lifespan. In eighteenth century, life expectancy in Europe was 39 years, while two centuries later, it was already 80 years. In 1900, the age median in the USA was 23 years, and a century later, it was already 36 years. Civilization diseases in fact reflect maladaptation to this phenomenon. In connection with the longer life expectancy, the lifestyle of population in advanced countries has dramatically changed – starting from unhealthy dietary habits over to the development of technologies allowing substantial reduction of physical activity in most human activities. Pandemic incidence of involutional osteoporosis and its implications have therefore become in recent decades one of the main healthcare priorities. Although a number of diagnostic (DXA, FRAX) and therapeutic procedures have been developed, we are increasingly aware of the need for a comprehensive approach to what we call “osteoporosis” and its incorporation into the context of the current geriatric medicine [2, 5, 35].

Keywords

Bone Mineral Density Fracture Risk Gait Speed Femoral Neck Fracture Geriatric Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Aspray TJ. New horizons in fracture risk assessment. Age Ageing. 2013;42:548–54.CrossRefPubMedGoogle Scholar
  2. 2.
    Binkley N, Krueger D, Buehring B. What is in the name revisited: should osteoporosis and sarcopenia be considered components of “dysmobility syndrome”. Osteoporos Int. 2013;24(12):2955–9.Google Scholar
  3. 3.
    Bischoff-Ferrari HA. Prevention of falls. Primer on the metabolic bone diseases and disorders of mineral metabolism. Am Soc Bone Miner Res. 2013;8:389–95.Google Scholar
  4. 4.
    Black DM, Rosen CJ. Following the bone density trail: a clinical perspective. J Clin Endocrinol Metab. 2012;97:1176–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Cooper C, Dere W, Evans W, et al. Frailty and sarcopenia: definitions and outcome parameters. Osteoporos Int. 2012;23:1839–48.CrossRefPubMedGoogle Scholar
  6. 6.
    Cummings SR, Black DM, Newitt MC, et al. Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group. JAMA. 1990;263(5):665–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Crilly RG, Kloseck M, Chesworth B, et al. Comparison of hip fracture and osteoporosis medication prescription rates across Canadian provinces. Osteoporos Int. Publ online 02 Aug 2013.Google Scholar
  8. 8.
    Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: european consensus on definition and diagnosis. Age Ageing. 2010;39:412–23.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Dukas L, Bischoff HA, Lindpaintner LS, et al. Alfacalcidol reduces the number of fallers in a community – dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc. 2004;52:230–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Dukas L, Schacht E, Mazor T, et al. Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of bellow 65 ml/min. Osteoporos Int. 2005;16:198–203.CrossRefPubMedGoogle Scholar
  11. 11.
    Evans WJ. Skeletal muscle effects on the skeleton. Primer on the metabolic bone diseases and disorders of mineral metabolism. Am Soc Bone Miner Res. 2013;8:978–85.Google Scholar
  12. 12.
    Fried LP. Frailty. In: Hazzards geriatric medicine and gerontology. New York: McGraw Hill; 2009. p. 631–45.Google Scholar
  13. 13.
    Fried LP, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med. 2001;56:146–56.CrossRefGoogle Scholar
  14. 14.
    Gast U, Belavy DL, Armbrecht G, et al. Bone density and neuromuscular function in older competitive athletes depend on running distance. Osteoporos Int. 2013;24:2033–42.CrossRefPubMedGoogle Scholar
  15. 15.
    Gregson CL, Dennison EM, Compston JE, et al. Disease specific perception of fracture risk and incident fracture rates: GLOW cohort study. Osteoporos Int. 2014;25(1):85–95.CrossRefPubMedGoogle Scholar
  16. 16.
    Gojda J. Úbytek svalové hmoty – kachexie vs. sarkopenie: komentovaný překlad. DMEV. 2011;14:97–8.Google Scholar
  17. 17.
    Guillemin F, Martinez L, Calvert M, et al. Fear of falling, fracture history, and comorbidities are associated with health-related quality of life among European and US women with osteoporosis in a large international study. Osteoporos Int. 2013;24(12):3001–10.CrossRefPubMedGoogle Scholar
  18. 18.
    Janssen I, et al. The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc. 2004;52:80–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Kemmler W, Haberle L, von Stengel S. Effects of exercise on fracture reduction in older adults. Osteoporos Int. 2013;24:1937–50.CrossRefPubMedGoogle Scholar
  20. 20.
    Kemmler W, von Stengel S, Bebenek M, et al. Exercise and fractures in postmenopausal women: a 12-year results of the Erlangen Fitness and Osteoporosis Prevention Study (EFOPS). Osteoporos Int. 2012;23:1267–76.CrossRefPubMedGoogle Scholar
  21. 21.
    Lang PO, Michel JP, Zekry D. Frailty syndrome: a transitional state in a dynamic process. Gerontology. 2009;55:539–49.CrossRefPubMedGoogle Scholar
  22. 22.
    Leavy B, Aberg AC, Melhus H, et al. When and where do hip fractures occur? Osteoporos Int. 2013;24:2387–96.CrossRefPubMedGoogle Scholar
  23. 23.
    Leslie WD, Lix LM. Comparison between various fracture risk assessment tools. Comparison between various fracture risk assessment tools. Osteoporos Int. 2014;25(1):1–21.CrossRefPubMedGoogle Scholar
  24. 24.
    Masud T, Binkley N, Boonen S, et al. Official positions for FRAX clinical regarding falls and frailty: can falls and frailty be used in FRAX? J Clin Densitom. 2011;14:194–204.CrossRefPubMedGoogle Scholar
  25. 25.
    Morley JE, Kim MJ, Haren MT, et al. Frailty and the ageing male. Ageing Male. 2005;8:135–40.CrossRefGoogle Scholar
  26. 26.
    Morley JE. Developing novel therapeutic approaches to frailty. Curr Prarm Des. 2009;15:3384–95.CrossRefGoogle Scholar
  27. 27.
    Richy F, Dukas L, Schacht E. Differential effects of D-hormone analogs and native vitamin D on the risk of falls: a comparative meta-analysis. Calcif Tissue Int. 2008;82:102–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Rolland Y, Van Kan GA, Gillete-Guyonnet S, et al. Strontium ranelate and risk of vertebral fractures in frail osteoporotic women. Bone. 2011;48(2):332–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Rosen C. Frailty: a D-ficiency syndrome of ageing. J Clin Endocrinol Metab. 2010;95:5210–2.CrossRefPubMedGoogle Scholar
  30. 30.
    Runge M, Hunter G. Determinants of musculoskeletal frailty and risk of falls in old age. J Musculoskeletal Neurola Interact. 2006;6:167–73.Google Scholar
  31. 31.
    Saltvedt I, Prestmo A, Einarsen E, et al. Development and delivery of patient treatment in the Trondheim Hip Fracture Trial. A new geriatric in-hospital pathway for elderly patients with hip fracture. BMC Res Notes. 2012;5:355.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Schacht E, Ringe JD. Alfacalcidol improves muscle power, muscle function and balance in elderly patients with reduced bone mass. Rheumatol Int. 2012;32(1):207–15.CrossRefPubMedGoogle Scholar
  33. 33.
    Schacht E. Reduction of falls and osteoporotic fractures: plain vitamin D or hormone analogs? Geriatr Gerontol Int. 2008;8 Suppl 1:S16–25.Google Scholar
  34. 34.
    Siris E, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164:1108–12.CrossRefPubMedGoogle Scholar
  35. 35.
    Siris ES, Boonen S, Mitchell PJ, et al. What is in the name? What constitutes the clinical diagnosis of osteoporosis? Osteoporos Int. 2012;23:2093–7. 2005;20(10):1813–9. Epub 2005 Jun 20.CrossRefPubMedGoogle Scholar
  36. 36.
    Sornay- Rendu E, Munoz F, Garnero P, et al. Identification of osteopenic women at high risk of fracture: the OFELY Study. J Bone Miner Res. 2005;20(10):1813–9. Epub 2005 Jun 20.Google Scholar
  37. 37.
    Studenski S, Perera S, Patel K, et al. Gait speed and survival rate in older adults. JAMA. 2011;305:50–8.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Syddall HE, Roberts HC, Evandrou M, et al. Prevalence and correlates of frailty among community – dwelling older men and women: findings from the Hertfordshire Cohort Study. Age Ageing. 2010;39(2):197–203.CrossRefPubMedGoogle Scholar
  39. 39.
    Syddall HE, Simmonds SJ, Martin HJ, et al. Cohort profile. The Hertfordshire ageing study. Int J Epidemiol. 2010;39:36–43.CrossRefPubMedGoogle Scholar
  40. 40.
    Tom SE, Adachi JD, Anderson FA, et al. Frailty and fracture, disability, and falls: a multiple country study from the Global Longitudinal Study of osteoporosis in women. J Am Geriatr Soc. 2013;61:327–34.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Topinkova E. Aging, disability and frailty. Ann Nutr Metab. 2008;52:6–11.CrossRefPubMedGoogle Scholar
  42. 42.
    de Vries OJ, Peeters GMEE, Lips P, et al. Does frailty predict increased risk of falls and fractures? Osteoporos Int. 2013;24:2397–404.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Department of Internal Medicine of 1st Facultyof MedicineCharles University and Central Military Hospital – Military University HospitalPragueCzech Republic

Personalised recommendations